Digital Product Passport for pharmaceuticals

No. Art. 1(2)(c) and (d) of the Ecodesign for Sustainable Products Regulation exclude medicinal products for human use and veterinary medicinal products, so no ESPR delegated act will cover a medicine. What is mandatory is serialisation under the Falsified Medicines Directive since 9 February 2019, and electronic product information once the pharmaceutical reform applies. A passport is a way to hold both plus everything around them in one structure, not a separate legal duty. What it gives you before then is a page behind every pack that shows the authorised information at readable size, in every language of the network, and keeps every superseded version for the audit.

No, and they should not be confused. The unique identifier is a serial number per pack, encoded in a Data Matrix, checked against the repositories system and decommissioned when the pack is dispensed. It exists to prove a pack is genuine. A passport identifier resolves to information about the product. They can sit on the same pack and even reference each other, but a passport never replaces verification against the repositories system, and no provider should suggest otherwise.

Yes. A manufacturing importer that places a medicine on the Union market carries the same obligations for the safety features as a Union manufacturer, including applying the identifier and uploading it before release. In practice the difficult part is contractual - third-country suppliers have to deliver identifier data and product information in a structured form. A scanned document is not a data delivery, and discovering that after the first shipment is expensive.

Electronic product information is the authorised summary of product characteristics, package leaflet and labelling in a structured electronic form, based on a common standard the EU regulatory network adopted after a pilot that ran from July 2023 to August 2024. Submission is voluntary today and strongly encouraged by EMA, which published guidance for the centralised procedure in September 2026. It becomes mandatory for newly authorised medicines once the revised pharmaceutical legislation applies, which EMA expects in 2028. Until the new Directive and Regulation are published in the Official Journal, treat that as an expectation and not as a deadline.

Not as such. The FMD product code has to allow identification of the product, and in most member states it is built on a GS1 GTIN or a national equivalent. If your product code rests on a GTIN, the identifier in Transpareo becomes a GS1 Digital Link that other systems resolve too. Without one the product gets a unique Transpareo identifier and the QR code leads to the same passport.

Pharmaceutical information is unusually stratified. Patient-facing content is regulated word by word, professional content differs from it, and manufacturing and audit records are not public at all. In Transpareo, visibility is a property of every data field, so the authorised product information can be public while batch records, temperature logs, supplier declarations and audit reports sit behind logged access for the readers entitled to them. The same code shows a different view depending on who is reading.

Only the authorised text, and only in the form it was authorised. Product information for medicines is not marketing copy and may not be rewritten, summarised or supplemented with promotional statements. Advertising prescription medicines to the general public is prohibited in the EU. The safe use of a passport in pharma is as a container for authorised content plus data that carries no promotional message at all - manufacturing origin, cold-chain evidence, disposal information.

That depends on what you want it to answer. Serialisation is already per pack and lives in the repositories system. A passport is usually more useful at product or batch level, where the authorised information, the manufacturing sites and the batch evidence sit. Transpareo supports batch-level and item-level passports through serial identifiers, so you can go down to the individual pack where there is a reason to, without generating millions of pages you never look at.

Longer than the shelf life, in every direction. Batch documentation has to be retrievable years after the last pack expired, and a pharmacovigilance question can reach back further still. A link printed on a carton therefore has to outlive the carton by a wide margin. Ask any provider what happens to your passports after a cancellation - with Transpareo, published passports stay reachable through a permanent address, and our provider checklist names the further questions worth asking.

For the safety features, penalties are set by the member states and enforced by the national competent authorities, and the practical consequence is worse than the fine - a pack that cannot be verified may not be dispensed, and a batch that cannot be decommissioned sits still. For the product information, an unauthorised or outdated text is a regulatory non-compliance that reaches the marketing authorisation itself. In both cases the cost is measured in stopped supply, not in the penalty notice.